查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553654

双相情感障碍市场规模、份额、趋势分析报告：按类型、药物类别、分销管道、地区和细分市场预测，2024-2030 年

Bipolar Disorder Market Size, Share & Trends Analysis Report By Type (Mood Stabilizer, Anticonvulsants, Antipsychotic Drugs), By Drug Class, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

双相情感障碍市场成长与趋势

Grand View Research, Inc.的最新报告显示，2024年至2030年，全球双极性情感障碍市场预计将以2.7%的复合年增长率成长，到2030年将达到58.7亿美元。

政府对提高双相情感障碍认识的支持以及有助于准确检测患者情绪和精神状态的技术进步是推动该市场成长的一些因素。

双相情感障碍盛行率的上升预计将在预测期内推动市场成长。政府措施也将支持市场成长。例如，国际双相情感障碍基金会的社会安全意外保险（SSDI）或补充保障收入（SSI）是美国社会安全局为受双相情感障碍影响的人们提供的计划。

此外，智慧型手机、智慧型手錶和穿戴式装置的技术进步透过有效捕捉生理、行为和环境资料来检测患者情绪和精神状态，从而提高了诊断率。线上自我管理工具还可以及时干预，从而提高该疾病的诊断和治疗率。然而，该市场重磅药物的专利到期可能会影响预测期内的市场动态。此外，预计双相情感障碍的治疗将面临学名药的激烈竞争。其他因素，例如与双相情感障碍治疗相关的副作用和双相情感障碍的误诊，可能会限制预测期内的市场成长。

双相情感障碍市场报告亮点

  • 由于双极性情感障碍的盛行率不断上升，情绪稳定剂细分市场将在 2023 年以 35.0% 的市场占有率占据主导地位。
  • 2023年，选择性血清素再回收抑制剂细分市场占25.0%的市占率。选择性血清素再回收抑制剂（SSRI）的功效和安全性推动了市场成长，可有效控制双相情感障碍引起的忧郁症状。
  • 2023年，医院药局领域以49.8%的份额占据市场主导地位。这一市场的成长是由于寻求心理健康诊断的患者数量不断增加。
  • 2023年，北美占据双极性情感障碍市场39.4%的份额。这是由于双相情感障碍病例数量不断增加以及该地区重要医疗设施的存在。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章双向情感障碍市场变数、趋势与范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 双极性情感障碍市场分析工具
    • 波特的分析
    • PESTEL分析

第 4 章 双极性情感障碍市场：按类型估计和趋势分析

  • 细分仪表板
  • 双极性情感障碍市场：2023 年和 2030 年类型变化分析
  • 情绪稳定剂
  • 抗惊厥药
  • 抗精神病药
  • 抗忧郁症
  • 抗焦虑药
  • 其他的

第五章双极性情感障碍市场：依药物类别估计与趋势分析

  • 细分仪表板
  • 双极性情感障碍市场：2023 年和 2030 年药物类别变化分析
  • 选择性血清素再回收抑制剂
  • 正肾上腺素再回收抑制剂
  • 三环抗忧郁药物
  • 单胺氧化酵素抑制剂
  • 苯二氮平类
  • β受体阻断剂
  • 其他的

第六章双向情感障碍市场：按分销管道的估计和趋势分析

  • 细分仪表板
  • 双极性情感障碍市场：2023 年和 2030 年分销管道波动分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章躁郁症市场：区域估计/趋势分析

  • 2023 年和 2030 年按地区分類的双相情感障碍市场占有率，百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Advanced Micro Devices
    • AstraZeneca
    • Eli Lilly and Company
    • GSK plc
    • Johnson &Johnson Services, Inc
    • Pfizer Inc.
    • AbbVie Inc.
    • Otsuka Holdings Co., Ltd.
    • Bristol-Myers Squibb Company
    • Teva Pharmaceutical Industries Ltd.
    • Sumitomo Pharma America, Inc
简介目录
Product Code: GVR-2-68038-033-0

Bipolar Disorder Market Growth & Trends:

The global bipolar disorder market is anticipated to reach USD 5.87 billion by 2030, growing at a CAGR of 2.7% from 2024 to 2030, according to a new report by Grand View Research, Inc. Government support for generating awareness about the bipolar disorder and technological advancements that facilitate accurate detection of a patient's mood and mental state are a few of the factors driving the growth of this market.

The rising prevalence of bipolar disorders is likely to propel market growth in the forecast period. Government initiatives also drive the market growth. For instance, International Bipolar Foundation's Social Security Disability Insurance (SSDI) or Supplemental Security Income (SSI) are programs offered by the Social Security Administration (U.S.) for the benefit of the people affected by bipolar disorder.

Besides, technological advancements in smartphones, smartwatches, and wearable devices improve diagnosis rates by capturing physiological, behavioral, and environmental data effectively to detect the patient's mood and mental state. Online self-management tools also result in timely intervention, thereby improving diagnosis rates and treatment rates for the disorder. However, the patent expiry of blockbuster drugs in this market is likely to impact market dynamics in the forecast period. Additionally, the drugs in the bipolar disorder market are bound to face intense competition from generic drugs, as treatment options for bipolar disorder. Other factors likely to restrain market growth in the forecast period include side effects associated with bipolar drugs, and misdiagnosis of bipolar disorder.

Bipolar Disorder Market Report Highlights:

  • The mood stabilizer segment dominated the market in 2023, with a share of 35.0% in 2023 due to the rising prevalence of bipolar disorder.
  • The selective serotonin reuptake inhibitor segment dominated the market in 2023, with a share of 25.0%. The factors responsible for the market growth are the efficacy and safety profile of selective serotonin reuptake inhibitors (SSRIs), which are effective in managing the depressive symptoms occurring due to bipolar disorder.
  • The hospital pharmacies segment dominated the market in 2023, with a share of 49.8% in 2023. This market growth was attributed to the increase in the number of patients seeking a diagnosis of their mental health.
  • North America dominated the bipolar disorder market with a market share of 39.4% in 2023. This was attributed to the increase in the cases of bipolar disorders and the presence of significant medical institutes in the region.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Bipolar Disorder Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Bipolar Disorder Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Bipolar Disorder Market: Type Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Bipolar Disorder Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Mood Stabilizer
    • 4.3.1. Mood Stabilizer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Anticonvulsants
    • 4.4.1. Anticonvulsant Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Antipsychotic Drugs
    • 4.5.1. Antipsychotic Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Antidepressant Drugs
    • 4.6.1. Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.7. Antianxiety Drugs
    • 4.7.1. Antianxiety Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.8. Other Types
    • 4.8.1. Other Types Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Bipolar Disorder Market: Drug Class Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Bipolar Disorder Market: Drug Class Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Selective Serotonin Reuptake Inhibitor
    • 5.3.1. Selective Serotonin Reuptake Inhibitor Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Serotonin Norepinephrine Reuptake Inhibitor
    • 5.4.1. Serotonin Norepinephrine Reuptake Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. Tricyclic Antidepressant Drugs
    • 5.5.1. Tricyclic Antidepressant Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Monoamine Oxidase Inhibitors
    • 5.6.1. Monoamine Oxidase Inhibitors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Benzodiazepines
    • 5.7.1. Benzodiazepines Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.8. Beta Blockers
    • 5.8.1. Beta Blockers Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.9. Other Drugs Classes
    • 5.9.1. Other Drugs Classes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Bipolar Disorder Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Bipolar Disorder Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Bipolar Disorder Market: Regional Estimates & Trend Analysis

  • 7.1. Bipolar Disorder Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Bipolar Disorder Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis by Key Market Participants
  • 8.2. Company Categorization
  • 8.3. Company Heat Map Analysis
  • 8.4. Company Profiles
    • 8.4.1. Advanced Micro Devices
      • 8.4.1.1. Participant's Overview
      • 8.4.1.2. Financial Performance
      • 8.4.1.3. Product Benchmarking
      • 8.4.1.4. Recent Developments/ Strategic Initiatives
    • 8.4.2. AstraZeneca
      • 8.4.2.1. Participant's Overview
      • 8.4.2.2. Financial Performance
      • 8.4.2.3. Product Benchmarking
      • 8.4.2.4. Recent Developments/ Strategic Initiatives
    • 8.4.3. Eli Lilly and Company
      • 8.4.3.1. Participant's Overview
      • 8.4.3.2. Financial Performance
      • 8.4.3.3. Product Benchmarking
      • 8.4.3.4. Recent Developments/ Strategic Initiatives
    • 8.4.4. GSK plc
      • 8.4.4.1. Participant's Overview
      • 8.4.4.2. Financial Performance
      • 8.4.4.3. Product Benchmarking
      • 8.4.4.4. Recent Developments/ Strategic Initiatives
    • 8.4.5. Johnson & Johnson Services, Inc
      • 8.4.5.1. Participant's Overview
      • 8.4.5.2. Financial Performance
      • 8.4.5.3. Product Benchmarking
      • 8.4.5.4. Recent Developments/ Strategic Initiatives
    • 8.4.6. Pfizer Inc.
      • 8.4.6.1. Participant's Overview
      • 8.4.6.2. Financial Performance
      • 8.4.6.3. Product Benchmarking
      • 8.4.6.4. Recent Developments/ Strategic Initiatives
    • 8.4.7. AbbVie Inc.
      • 8.4.7.1. Participant's Overview
      • 8.4.7.2. Financial Performance
      • 8.4.7.3. Product Benchmarking
      • 8.4.7.4. Recent Developments/ Strategic Initiatives
    • 8.4.8. Otsuka Holdings Co., Ltd.
      • 8.4.8.1. Participant's Overview
      • 8.4.8.2. Financial Performance
      • 8.4.8.3. Product Benchmarking
      • 8.4.8.4. Recent Developments/ Strategic Initiatives
    • 8.4.9. Bristol-Myers Squibb Company
      • 8.4.9.1. Participant's Overview
      • 8.4.9.2. Financial Performance
      • 8.4.9.3. Product Benchmarking
      • 8.4.9.4. Recent Developments/ Strategic Initiatives
    • 8.4.10. Teva Pharmaceutical Industries Ltd.
      • 8.4.10.1. Participant's Overview
      • 8.4.10.2. Financial Performance
      • 8.4.10.3. Product Benchmarking
      • 8.4.10.4. Recent Developments/ Strategic Initiatives
    • 8.4.11. Sumitomo Pharma America, Inc
      • 8.4.11.1. Participant's Overview
      • 8.4.11.2. Financial Performance
      • 8.4.11.3. Product Benchmarking
      • 8.4.11.4. Recent Developments/ Strategic Initiatives